Journal of Clinical Endocrinology & Metabolism, Vol 80, 1670-1676, Copyright © 1995 by Endocrine Society

ARTICLES

Insulin-like growth factor II in uterine smooth-muscle tumors: maintenance of genomic imprinting in leiomyomata and loss of imprinting in leiomyosarcomata

TH Vu, C Yballe, S Boonyanit and AR Hoffman
Medical Service, VA Medical Center, Palo Alto, California 94304, USA.

Uterine leiomyosarcomata, malignant smooth-muscle tumors that may arise from existing leiomyomata or directly from the myometrium, have been shown to oversecrete insulin-like growth factor II (IGF-II). It has been shown recently that the IGF-II gene (IGF2) is maternally imprinted in both mice and humans. Only the paternal allele of IGF2 is usually expressed, except in adult liver and in the central nervous system in which biallelic expression is seen. Recently, loss of IGF2 imprinting has been reported in Wilms' tumor and in several other malignancies, and it has been suggested that biallelic expression of the gene leads to overexpression of IGF-II peptide and increased mitogenic activity. Using the ApaI restriction enzyme polymorphism in exon 9 of IGF2, we examined the expression of IGF2 in five informative uterine leiomyosarcomata and found that IGF2 was expressed biallelically in two tumors. In contrast, five samples of normal myometrium and six informative benign uterine leiomyomata showed monoallelic expression of IGF2. The incidence of heterozygosity at this locus was markedly lower in patients with leiomyosarcoma (6%) than in the healthy population (42% heterozygous; P < 0.01). H19, a gene that is imprinted in normal tissues, was expressed monoallelically in all informative normal and neoplastic uterine tumors. In contrast, the IGF-II receptor gene was expressed from both alleles in all tissues examined, confirming the finding that the human IGF-II receptor gene is not imprinted in humans. This study provides further evidence that relaxation of IGF2 genomic imprinting occurs not only in childhood tumors but also in adult-onset tumors, and it suggests a novel epigenetic mechanism for oncogenesis throughout life.

This article has been cited by other articles:

				J. D. Ravenel, K. W. Broman, E. J. Perlman, E. L. Niemitz, T. M. Jayawardena, D. W. Bell, D. A. Haber, H. Uejima, and A. P. Feinberg Loss of Imprinting of Insulin-Like Growth Factor-II (IGF2) Gene in Distinguishing Specific Biologic Subtypes of Wilms Tumor J Natl Cancer Inst, November 21, 2001; 93(22): 1698 - 1703. [Abstract] [Full Text] [PDF]

				I. M. Morison, M. R. Eccles, and A. E. Reeve Imprinting of insulin-like growth factor 2 is modulated during hematopoiesis Blood, November 1, 2000; 96(9): 3023 - 3028. [Abstract] [Full Text] [PDF]

				J. G. Falls, D. J. Pulford, A. A. Wylie, and R. L. Jirtle Genomic Imprinting: Implications for Human Disease Am. J. Pathol., March 1, 1999; 154(3): 635 - 647. [Abstract] [Full Text] [PDF]

				E. Adriaenssens, L. Dumont, S. Lottin, D. Bolle, A. Lepretre, A. Delobelle, F. Bouali, T. Dugimont, J. Coll, and J.-J. Curgy H19 Overexpression in Breast Adenocarcinoma Stromal Cells Is Associated with Tumor Values and Steroid Receptor Status but Independent of p53 and Ki-67 Expression Am. J. Pathol., November 1, 1998; 153(5): 1597 - 1607. [Abstract] [Full Text] [PDF]

				J.-F. Hu, H. Oruganti, T. H. Vu, and A. R. Hoffman Tissue-Specific Imprinting of the Mouse Insulin-Like Growth Factor II Receptor Gene Correlates with Differential Allele-Specific DNA Methylation Mol. Endocrinol., February 1, 1998; 12(2): 220 - 232. [Abstract] [Full Text]

				J.-F. Hu, P. H. Nguyen, N. V. Pham, T. H. Vu, and A. R. Hoffman Modulation of Igf2 Genomic Imprinting in Mice Induced by 5-Azacytidine, an Inhibitor of DNA Methylation Mol. Endocrinol., December 1, 1997; 11(13): 1891 - 1898. [Abstract] [Full Text] [PDF]

				C. Gicquel, M.-L. Raffin-Sanson, V. Gaston, X. Bertagna, P.-F. Plouin, M. Schlumberger, A. Louvel, J.-P. Luton, and Y. Le Bouc Structural and Functional Abnormalities at 11p15 Are Associated with the Malignant Phenotype in Sporadic Adrenocortical Tumors: Study on a Series of 82 Tumors J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2559 - 2565. [Abstract] [Full Text] [PDF]

				W.-H. Wang, J.-X. Duan, T. H. Vu, and A. R. Hoffman Increased Expression of the Insulin-like Growth Factor-II Gene in Wilms' Tumor Is Not Dependent on Loss of Genomic Imprinting or Loss of Heterozygosity J. Biol. Chem., November 1, 1996; 271(44): 27863 - 27870. [Abstract] [Full Text] [PDF]

				M. Nagamani and C. A. Stuart Specific Receptors and Growth Effects of Insulin and Insulin-Like Growth Factors in a Human Cell Line Derived From Mixed Mesodermal Tumor of the Uterus Reproductive Sciences, September 1, 1996; 3(5): 281 - 288. [Abstract] [PDF]

				J.-F. Hu, T. H. Vu, and A. R. Hoffman Promoter-specific Modulation of Insulin-like Growth Factor II Genomic Imprinting by Inhibitors of DNA Methylation J. Biol. Chem., July 26, 1996; 271(30): 18253 - 18262. [Abstract] [Full Text] [PDF]

				S. Zhan, D. Shapiro, S. Zhan, L. Zhang, S. Hirschfeld, J. Elassal, and L. J. Helman Concordant Loss of Imprinting of the Human Insulin-like Growth Factor II Gene Promoters in Cancer J. Biol. Chem., November 24, 1995; 270(47): 27983 - 27986. [Abstract] [Full Text] [PDF]